Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
St. Jude Children's Research Hospital
UNICANCER
Norwegian University of Science and Technology
National Cancer Institute (NCI)
Children's Hospital Los Angeles
Northwestern University
Case Comprehensive Cancer Center
Radiation Therapy Oncology Group
Memorial Sloan Kettering Cancer Center
Duke University
University of California, San Francisco
Dana-Farber Cancer Institute
University of Minnesota
University of South Florida
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Novartis
Duke University
Asan Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Assistance Publique - Hôpitaux de Paris
Daiichi Sankyo
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Miami
Pediatric Brain Tumor Consortium
St. Jude Children's Research Hospital